The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Babar Bashir
Consulting or Advisory Role - Merck/Eisai
Research Funding - Amgen (Inst); Artios (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Lilly (Inst); Elucida Oncology (Inst); Gritstone Bio (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); KAHR Medical (Inst); Lyell Immunopharma (Inst); Merck (Inst); Pionyr (Inst); RasCal (Inst); Syros Pharmaceuticals (Inst); Tarveda Therapeutics (Inst)
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Reuven Chantre
Employment - Chemomab Therapeutics
Stock and Other Ownership Interests - Chemomab Therapeutics; Pluristem Therapeutics
 
Shira Amsili
Employment - KAHR Medical
Stock and Other Ownership Interests - KAHR Medical
 
Rinat Tabakman
Employment - KAHR Medical
Stock and Other Ownership Interests - KAHR Medical
 
Yaffa Shwartz
Employment - KAHR Medical
Stock and Other Ownership Interests - KAHR Medical
 
Adam Foley-Comer
Employment - KAHR Medical
Leadership - KAHR Medical
Stock and Other Ownership Interests - KAHR Medical
 
Antonio Jimeno
Stock and Other Ownership Interests - Champions Oncology; Suvica
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cantargia AB (Inst); Celldex (Inst); Debiopharm Group (Inst); Genocea Biosciences (Inst); HolyStone Therapeutics (Inst); Iovance Biotherapeutics (Inst); KHAR Medical (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); SQZ Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Suvica